ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density
暂无分享,去创建一个
A. Dahan | A. Cerami | M. Niesters | M. Tannemaat | O. Vogels | E. Sarton | M. Brines | Ann N Dunne | Maarten Swartjes | L. Heij | P. Proto | M. Velzen
[1] A. Dahan,et al. Corneal nerve quantification predicts the severity of symptoms in sarcoidosis patients with painful neuropathy , 2013 .
[2] P. Ghezzi,et al. The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model , 2013, Neuroscience.
[3] A. Dahan,et al. The erythropoietin analog ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain , 2013 .
[4] A. Dahan,et al. Sarcoidosis and Pain Caused by Small-Fiber Neuropathy , 2012, Pain research and treatment.
[5] A. Dahan,et al. Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study , 2012, Molecular medicine.
[6] Kevin W Eliceiri,et al. NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.
[7] A. Cerami,et al. The Receptor That Tames the Innate Immune Response , 2012, Molecular medicine.
[8] S. Saidha,et al. Detection of Clinical and Subclinical Retinal Abnormalities in Neurosarcoidosis with Optical Coherence Tomography (S08.001) , 2012 .
[9] S. Saidha,et al. Detection of clinical and subclinical retinal abnormalities in neurosarcoidosis with optical coherence tomography , 2012, Journal of Neurology.
[10] A. Dahan,et al. ARA290, a Peptide Derived from the Tertiary Structure of Erythropoietin, Produces Long-term Relief of Neuropathic Pain: An Experimental Study in Rats and &bgr;-Common Receptor Knockout Mice , 2011, Anesthesiology.
[11] D. Moller,et al. Sarcoidosis—scientific progress and clinical challenges , 2011, Nature Reviews Rheumatology.
[12] A. Vinik,et al. Neuropathy in prediabetes: does the clock start ticking early? , 2011, Nature Reviews Endocrinology.
[13] A. Prasse,et al. Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. , 2011, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.
[14] J. Casillas,et al. DETERMINING THE MINIMAL CLINICALLY IMPORTANT 1 DIFFERENCE FOR THE SIX-MINUTE WALK TEST AND THE 2002 METER FAST WALK TEST DURING CARDIAC REHABILITATION 3 PROGRAM IN CORONARY ARTERY DISEASE PATIENTS AFTER 4 ACUTE CORONARY SYNDROME , 2017 .
[15] A. Lenssen,et al. Exercise capacity, muscle strength and fatigue in sarcoidosis , 2011, European Respiratory Journal.
[16] J. Tavee,et al. Sarcoidosis and Small-fiber Neuropathy , 2011, Current pain and headache reports.
[17] Mitra Tavakoli,et al. Corneal confocal microscopy: a novel non-invasive technique to quantify small fibre pathology in peripheral neuropathies. , 2011, Journal of visualized experiments : JoVE.
[18] A. Vinik,et al. Topiramate improves neurovascular function, epidermal nerve fiber morphology, and metabolism in patients with type 2 diabetes mellitus , 2010, Diabetes, metabolic syndrome and obesity : targets and therapy.
[19] R. Freeman,et al. Capsaicin induces degeneration of cutaneous autonomic nerve fibers , 2010, Annals of neurology.
[20] C. Schmitz,et al. Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study , 2010, Journal of the peripheral nervous system : JPNS.
[21] G. Lauria,et al. Pain and autonomic dysfunction in patients with sarcoidosis and small fibre neuropathy , 2010, Journal of Neurology.
[22] M. Dusch,et al. Nerve growth factor‐evoked nociceptor sensitization in pig skin in vivo , 2010, Journal of neuroscience research.
[23] J. Valls-Solé,et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Fe‐deration of Neurological Societies and the Peripheral Nerve Society , 2010, European journal of neurology.
[24] C. Sommer,et al. Elevated proinflammatory cytokine expression in affected skin in small fiber neuropathy , 2010, Neurology.
[25] M. Nolano,et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society , 2010, Journal of the peripheral nervous system : JPNS.
[26] 陶仲为. Sarcoidosis , 2009 .
[27] G. Lauria,et al. Intraepidermal nerve fiber density and its application in sarcoidosis , 2009, Neurology.
[28] J. Tavee,et al. Small fiber neuropathy: A burning problem , 2009, Cleveland Clinic Journal of Medicine.
[29] Michael A. Yamin,et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin , 2008, Proceedings of the National Academy of Sciences.
[30] Nathan Efron,et al. Surrogate Markers of Small Fiber Damage in Human Diabetic Neuropathy , 2007, Diabetes.
[31] R. Baughman,et al. Six-minute walk test and health status assessment in sarcoidosis. , 2007, Chest.
[32] Y. Chan,et al. Determinants of epidermal nerve fiber density in normal individuals , 2006, Muscle & nerve.
[33] P. Ghezzi,et al. Protective Effect of Erythropoietin and Its Carbamylated Derivative in Experimental Cisplatin Peripheral Neurotoxicity , 2006, Clinical Cancer Research.
[34] D. Yue,et al. The Level of Small Nerve Fiber Dysfunction Does not Predict Pain in Diabetic Neuropathy: A Study Using Quantitative Sensory Testing , 2006, The Clinical journal of pain.
[35] R. Treede,et al. Quantitative sensory testing: a comprehensive protocol for clinical trials , 2006, European journal of pain.
[36] Justin C McArthur,et al. The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. , 2004, Brain : a journal of neurology.
[37] P. Ghezzi,et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[38] J. de Vries,et al. Impact of pain in a Dutch sarcoidosis patient population. , 2003, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.
[39] C. Sommer,et al. Small fibre neuropathy in sarcoidosis , 2002, The Lancet.
[40] Marc Rendell,et al. Efficacy and Safety of Recombinant Human Nerve Growth Factor in Patients With Diabetic Polyneuropathy: A Randomized Controlled Trial , 2000 .
[41] G. Hunninghake,et al. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. , 1999, The European respiratory journal.
[42] M. Decramer,et al. Six minute walking distance in healthy elderly subjects. , 1999, The European respiratory journal.
[43] G. Rizzato. Hot issues from the fifth WASOG meeting Essen Germany, September 17-19 1997. World Association for Sarcoidosis and Other Granulomatous Disorders. , 1997, The European respiratory journal.
[44] D. Tanelian,et al. Altered thermal responsiveness during regeneration of corneal cold fibers. , 1995, Journal of neurophysiology.
[45] J. de Vries,et al. The small fiber neuropathy screening list: Construction and cross-validation in sarcoidosis. , 2011, Respiratory medicine.
[46] M. Judson,et al. Small fiber neuropathy in sarcoidosis: Something beneath the surface. , 2011, Respiratory medicine.
[47] P J Dyck,et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. , 2000, JAMA.
[48] Surrogate markers , 1998 .